David L Becton, MD
Full Member
|
| Research Program:
Cancer Therapeutics
Faculty Rank:
Professor
Campus:
Arkansas Children's Hospital
College:
College of Medicine
Department:
Pediatrics
|
Contact Information
- Email Address: BECTONDAVIDL@UAMS.EDU
- Profiles Research Networking Software: View Profile
Open Clinical Trials
- “ACCL1931 A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy” (NCT05602194)
- “BCC015 - Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma” (NCT02154490)
- “AALL1732 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-Lly” (NCT03959085)
- “ARST2032 Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma” (NCT05304585)
- “AGCT1532 A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors” (NCT02582697)
Recent Publications
- Gill PS, Yu FB, Porter-Gill PA, [et al., including Becton DL]. Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. Journal of personalized medicine. 2021 11(5). PMID: 34064668. PMCID: PMC8150685.
- Mack JM, Pierce CD, Richter GT, [et al., including Becton D]. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography. Pediatric blood & cancer. 2020:e28824. PMID: 33211399.
- Minard-Colin V, Aupérin A, Pillon M, [et al., including Becton D]. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. The New England journal of medicine. 2020 382(23):2207-2219. PMID: 32492302. PMCID: PMC7720281.